Cardiovascular Key Lab of Zhejiang Province, Department of Cardiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
J Zhejiang Univ Sci B. 2013 Aug;14(8):670-5. doi: 10.1631/jzus.BQICC702.
Transcatheter valve implantation or repair has been a very promising approach for the treatment of valvular heart diseases since transcatheter aortic valve implantation (TAVI) was successfully performed in 2002. Great achievements have been made in this field (especially TAVI and transcatheter mitral valve repair--MitraClip system) in recent years. Evidence from clinical trials or registry studies has proved that transcatheter valve treatment for valvular heart diseases is safe and effective in surgical high-risk or inoperable patients. As the evidence accumulates, transcatheter valve treatment might be an alterative surgery for younger patients with surgically low or intermediate risk valvular heart diseases in the near future. In this paper, the updates on transcatheter valve treatment are reviewed.
自 2002 年经导管主动脉瓣植入术（TAVI）成功实施以来，经导管瓣膜植入或修复已成为治疗心脏瓣膜病的一种极有前途的方法。近年来，该领域（尤其是 TAVI 和经导管二尖瓣修复-MitraClip 系统）取得了重大进展。临床试验或注册研究的证据证明，对于手术高危或不可手术的患者，经导管瓣膜治疗心脏瓣膜病是安全有效的。随着证据的积累，在不久的将来，经导管瓣膜治疗可能成为手术低危或中危心脏瓣膜病的年轻患者的替代手术。本文综述了经导管瓣膜治疗的最新进展。
